Literature DB >> 7929752

Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods.

M A Pfaller1, M Bale, B Buschelman, M Lancaster, A Espinel-Ingroff, J H Rex, M G Rinaldi.   

Abstract

The National Committee for Clinical Laboratory Standards has developed a proposed standard method for in vitro antifungal susceptibility testing of yeast isolates (National Committee for Clinical Laboratory Standards, document M27-P, 1992). In order for antifungal testing by the M27-P method to be accepted, reliable quality control (QC) performance criteria must be developed. In the present study, five laboratories tested 10 candidate QC strains 20 times each against three antifungal agents: amphotericin B, fluconazole, and 5-fluorocytosine. All sites conformed to the M27-P standards and used a common lot of tube dilution reagents and RPMI 1640 broth medium. Overall, 98% of MIC results with amphotericin B, 95% with fluconazole, and 92% with 5-fluorocytosine fell within the desired 3-log2 dilution range (mode +/- 1 log2 dilution). Excellent performance with all three antifungal agents was observed for six strains: Candida albicans ATCC 90028, Candida parapsilosis ATCC 90018, C. parapsilosis ATCC 22019, Candida krusei ATCC 6258, Candida tropicalis ATCC 750, and Saccharomyces cerevisiae ATCC 9763. With these strains, 3-log2 dilution ranges encompassing 94 to 100% of MICs for all three drugs were established. Additional studies with multiple lots of RPMI 1640 test medium will be required to establish definitive QC ranges.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929752      PMCID: PMC263751          DOI: 10.1128/jcm.32.7.1650-1653.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

Review 1.  Standardization of antifungal susceptibility testing.

Authors:  J N Galgiani; M G Rinaldi; A M Polak; M A Pfaller
Journal:  J Med Vet Mycol       Date:  1992

2.  Fluconazole resistance in AIDS patients.

Authors:  L Willocks; C L Leen; R P Brettle; D Urquhart; T B Russell; L J Milne
Journal:  J Antimicrob Chemother       Date:  1991-12       Impact factor: 5.790

Review 3.  Treatment of opportunistic fungal infections.

Authors:  D Armstrong
Journal:  Clin Infect Dis       Date:  1993-01       Impact factor: 9.079

Review 4.  Antifungal susceptibility testing.

Authors:  J H Rex; M A Pfaller; M G Rinaldi; A Polak; J N Galgiani
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

Review 5.  Antifungal susceptibility testing. Current state of technology, limitations, and standardization.

Authors:  M A Pfaller; M G Rinaldi
Journal:  Infect Dis Clin North Am       Date:  1993-06       Impact factor: 5.982

6.  Fluconazole resistance in Candida glabrata.

Authors:  C A Hitchcock; G W Pye; P F Troke; E M Johnson; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

7.  Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts.

Authors:  R A Fromtling; J N Galgiani; M A Pfaller; A Espinel-Ingroff; K F Bartizal; M S Bartlett; B A Body; C Frey; G Hall; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

8.  The spectrum of non-Candida fungal infections following bone marrow transplantation.

Authors:  V A Morrison; R J Haake; D J Weisdorf
Journal:  Medicine (Baltimore)       Date:  1993-03       Impact factor: 1.889

Review 9.  Impact of the changing epidemiology of fungal infections in the 1990s.

Authors:  M Pfaller; R Wenzel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-04       Impact factor: 3.267

10.  Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. The Norwegian Yeast Study Group.

Authors:  P Sandven; A Bjørneklett; A Maeland
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

View more
  25 in total

1.  Susceptibility of Candida species to photodynamic effects of photofrin.

Authors:  Joseph M Bliss; Chad E Bigelow; Thomas H Foster; Constantine G Haidaris
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

2.  Quantification of the APE2 gene expression level in Candida albicans clinical isolates from patients with diagnosed fungal infections.

Authors:  M Staniszewska; M Bondaryk; K Żukowski; M Chudy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-04-16       Impact factor: 3.267

3.  Lot-to-lot variability of antibiotic medium 3 used for testing susceptibility of Candida isolates to amphotericin B.

Authors:  M Lozano-Chiu; P W Nelson; M Lancaster; M A Pfaller; J H Rex
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

4.  In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles.

Authors:  F Barchiesi; L Falconi Di Francesco; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

5.  Variations in fluconazole susceptibility and DNA subtyping of multiple Candida albicans colonies from patients with AIDS and oral candidiasis suffering one or more episodes of infection.

Authors:  S W Redding; M A Pfaller; S A Messer; J A Smith; J Prows; L L Bradley; A W Fothergill; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

6.  Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole.

Authors:  J H Rex; M A Pfaller; M Lancaster; F C Odds; A Bolmström; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

7.  Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine.

Authors:  M A Pfaller; M Bale; B Buschelman; M Lancaster; A Espinel-Ingroff; J H Rex; M G Rinaldi; C R Cooper; M R McGinnis
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

8.  In vitro activity of a new polyene, SPA-S-843, against yeasts.

Authors:  C Rimaroli; T Bruzzese
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 9.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

10.  Mycotic keratitis due to Aspergillus nomius.

Authors:  Palanisamy Manikandan; János Varga; Sándor Kocsubé; Robert A Samson; Raghavan Anita; Rajaraman Revathi; Ilona Dóczi; Tibor Mihály Németh; Venkatapathy Narendran; Csaba Vágvölgyi; Chockaiya Manoharan; László Kredics
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.